Compound & BioSample Management 2017 Market Trend Report

Pharma IQ

Download Your Copy

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

Compound management and biological sample management both have significant influence in the drug discovery process. Compounds of a high integrity contribute to reliable results when locating drug candidates. Additionally, the collection, storage and distribution of human biological materials supports the advancement of the R&D industry, aids understanding of the mechanisms of diseases and fuels the trend to provide personalised medicines.

Last year in Pharma IQ’s Compound Management and Biobanking Activity tracker, around 20 compound management industry members and 28 biobanking industry members examined and pinpointed the most recent trends in both markets over the past year and the predicted trends on the horizon.

In the report both industries highlighted automation as a beneficial technique for minimising errors and improving workflow efficiency. Our participants both in the biobanking and compound management sectors had some level of investment planned for technology and software scheduled over the following 12 months. However, our compound participants showed consensus that there was a gradual slow in the buzz behind automation as the sector settled down with their robotics option of choice and focused on refining their detailing. A minority of our biobanking experts expressed a lack of confidence in robotics systems.


It was evident in the findings that sample quality was to remain a prime focus across the two markets. With sustainability levels in biobanking standing as a traditional challenge leading some biobanks to close their doors, the move to concentrate upon the quality and the actual usability of samples will look to conquer this hurdle. This is being fused with the focus to land public-private partnerships.

Team sizes saw a plateau especially on the compound management side. A slow growth was indicated within both industries, signifying an encouraging level of stability. This year, we revisit the compound and biobanking markets to pinpoint any shifts or new trends in the market.

This year, we revisit the compound and biobanking markets to pinpoint any shifts or new trends in the market.